🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's Disease

RecruitingNAAges 55 Years - anyAllAlzheimercentrum Amsterdam
NCT07680335 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Cognitive disorders have a broad differential diagnosis, and a precise, timely diagnosis is essential for personalized treatment and care. Currently, dementia diagnoses are often not further specified according to the underlying pathology and are frequently delayed by several years. However, with the upcoming disease-modifying treatments (DMTs) for AD, an accurate, pathology-driven (i.e., etiological) diagnosis will become necessary. Blood-based biomarkers (BBMs) are promising tools for detecting Alzheimer's disease (AD), with current research showing high concordance with cerebrospinal fluid (CSF) biomarkers and amyloid PET imaging. However, it remains unclear how physicians would value the availability of BBMs for AD in routine clinical practice. The investigators hypothesize that BBMs will benefit both patients and physicians in the diagnostic process within a memory clinic setting.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patient presents in memory clinic with cognitive complaints. * The physician is concerned about underlying AD as etiology of the complaints. * Adequate fluency in Dutch to understand informed consent procedure. Exclusion Criteria: * Age under 55. * Previous biomarker-confirmed diagnosis of AD. * Alcohol or drug abuse to such an extent that treatment would be advisable. * Patient is incapacitated, and is not able to judge consequences of participation.
💊

What it tests

  • Plasma p-tau217 and neurofilament light chain results
📍

Where

8 sites
Amsterdam UMC
Amsterdam, Netherlands
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, Netherlands
Flevoziekenhuis
Almere Stad, Netherlands
Spaarne Gasthuis
Haarlem, Netherlands
Tergooi MC
Hilversum, Netherlands
Frisius MC
Leeuwarden, Netherlands
Dijklander Ziekenhuis
Purmerend, Netherlands
Elisabeth-TweeSteden Ziekenhuis
Tilburg, Netherlands
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy